Avidity of anti-neurocytoskeletal antibodies in cerebrospinal fluid and serum
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem
- MeSH
- afinita protilátek MeSH
- dospělí MeSH
- imunoglobulin G krev mozkomíšní mok imunologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- neurofilamentové proteiny imunologie MeSH
- proteiny tau imunologie MeSH
- protilátky anti-idiotypické krev mozkomíšní mok imunologie MeSH
- roztroušená skleróza krev mozkomíšní mok imunologie MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
- Názvy látek
- imunoglobulin G MeSH
- neurofilament protein L MeSH Prohlížeč
- neurofilament protein M MeSH Prohlížeč
- neurofilamentové proteiny MeSH
- proteiny tau MeSH
- protilátky anti-idiotypické MeSH
Antibodies have different avidities that can be evaluated using modified enzyme-linked immunosorbent assay (ELISA) techniques. We determined levels and avidities of antibodies to light (NFL) and medium (NFM) subunits of neurofilaments and tau protein in serum and cerebrospinal fluid (CSF) from 26 patients and anti-tau antibody levels and their avidities in 20 multiple sclerosis (MS) patients and 20 age- and sex-matched controls. Each sample was analyzed using both standard ELISA and also using a similar ELISA protocol with the addition of urea. The avidities of anti-neurocytoskeletal antibodies were higher in the CSF than those in serum (anti-NFL, p < 0.0001; anti-tau, p < 0.01; anti-NFM, n.s.). There was no relationship between avidities in serum and CSF for individual anti-neurocytoskeletal antibodies. We did not observe the relationship among the avidities of various anti-neurocytoskeletal antibodies. The avidities of anti-tau antibodies in the CSF were significantly higher in the MS patients than those in the controls (p < 0.0001). The study demonstrates the differences in avidities of CSF or serum neurocytoskeletal antibodies measured as the urea resistance by ELISA method. Avidity determination of anti-neurocytoskeletal antibodies could contribute to the evaluation of the immunological status of patients.
Zobrazit více v PubMed
Folia Biol (Praha). 2009;55(1):23-6 PubMed
Ann Neurol. 1983 Mar;13(3):227-31 PubMed
Neurol Sci. 2003 Dec;24 Suppl 5:S279-82 PubMed
Neurosci Lett. 2004 Jun 3;363(1):14-7 PubMed
J Neurol. 2007 Jan;254(1):20-5 PubMed
N Engl J Med. 2003 Jul 10;349(2):139-45 PubMed
Lab Invest. 2008 Aug;88(8):796-807 PubMed
J Neuroimmunol. 2006 Nov;180(1-2):29-32 PubMed
Acta Neurol Scand. 2007 Aug;116(2):100-7 PubMed
Acta Neurol Scand. 2005 Feb;111(2):114-7 PubMed
J Med Virol. 1997 Jul;52(3):275-9 PubMed
Mol Immunol. 1993 Aug;30(12):1133-42 PubMed
Alzheimer Dis Assoc Disord. 2006 Jul-Sep;20(3):127-32 PubMed
Neurology. 1996 Apr;46(4):907-11 PubMed
Eur J Neurol. 2007 Dec;14(12):1329-33 PubMed
Clin Immunol. 2005 Jul;116(1):77-82 PubMed
Neurosci Lett. 2006 Dec 20;410(2):90-3 PubMed
Mult Scler. 2005 Oct;11(5):532-6 PubMed
Neurology. 1983 Nov;33(11):1444-52 PubMed
Ann Neurol. 2001 Jul;50(1):121-7 PubMed
Clin Diagn Lab Immunol. 2004 Jul;11(4):669-74 PubMed
J Neuroimmunol. 2003 Jun;139(1-2):76-80 PubMed
J Clin Microbiol. 2005 Jun;43(6):2793-7 PubMed
Clin Diagn Lab Immunol. 1996 Mar;3(2):211-5 PubMed
J Clin Microbiol. 2005 Nov;43(11):5784-6 PubMed
Neurosci Lett. 2001 Mar 9;300(2):95-8 PubMed
Eur J Neurol. 2008 Nov;15(11):1173-9 PubMed
Brain Res Bull. 2006 Jan 15;68(4):213-6 PubMed
J Neuropathol Exp Neurol. 2007 Apr;66(4):295-304 PubMed
Neurology. 2002 May 14;58(9):1372-81 PubMed
